Contribute Try STAT+ Today
Trending:
Coronavirus
Health
Biotech
First Opinion
The Readout

Moderna’s patent problems & clocking the CRISPR race

By Damian Garde @damiangarde and Meghana Keshavan @megkesh

May 17, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for May 17, 2017

About the Authors Reprints

Damian Garde

National Biotech Reporter

Damian covers biotech and writes The Readout newsletter.

Meghana Keshavan

Biotech Correspondent

Meghana covers biotech from Los Angeles and contributes to The Readout newsletter.

Trending
Vaccine black background
The curse of the incidental illness: Seen as side…
The curse of the incidental illness: Seen as side effects to Covid vaccinations, ailments may have…
A tale of two ampoules
A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines
A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines
Pfizer freezer farm
The story of mRNA: How a once-dismissed idea became…
The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine…
Recommended
The READOUT
Biden’s Covid-19 plan, Woodcock for FDA chief, & Aurinia…
Biden’s Covid-19 plan, Woodcock for FDA chief, & Aurinia shows and tells
The READOUT
#JPM21: A biotech IPO record in play, Talkspace goes public,…
#JPM21: A biotech IPO record in play, Talkspace goes public, & vaccine talk
The READOUT
#JPM21: Unicorn down, Bayer’s gene therapy team, and a…
#JPM21: Unicorn down, Bayer’s gene therapy team, and a windfall for testing companies

More in The Readout

The READOUT
The Readout

Biden’s Covid-19 plan, Woodcock for FDA chief, & Aurinia shows and tells

By Meghana Keshavan

The READOUT
The Readout

#JPM21: A biotech IPO record in play, Talkspace goes public, & vaccine talk

By Damian Garde

The READOUT
The Readout

#JPM21: Unicorn down, Bayer’s gene therapy team, and a windfall for testing companies

By Damian Garde

The READOUT
The Readout

#JPM21: M&As are MIA, another amyloid debate, & adjusting to virtuality

By Damian Garde

The READOUT
The Readout

Sarepta’s gene therapy disappoints, beyond vaccines for mRNA, & what a Democratic Senate means for biotech

By Meghana Keshavan